A detailed history of Two Sigma Investments, LP transactions in Oramed Pharmaceuticals Inc. stock. As of the latest transaction made, Two Sigma Investments, LP holds 141,683 shares of ORMP stock, worth $335,788. This represents 0.0% of its overall portfolio holdings.

Number of Shares
141,683
Previous 150,367 5.78%
Holding current value
$335,788
Previous $386,000 10.62%
% of portfolio
0.0%
Previous 0.0%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$2.21 - $2.63 $19,191 - $22,838
-8,684 Reduced 5.78%
141,683 $345,000
Q2 2024

Aug 14, 2024

BUY
$2.07 - $2.83 $32,939 - $45,033
15,913 Added 11.84%
150,367 $386,000
Q1 2024

May 15, 2024

SELL
$2.18 - $3.58 $49,869 - $81,896
-22,876 Reduced 14.54%
134,454 $392,000
Q4 2023

Feb 14, 2024

BUY
$1.71 - $2.57 $215,126 - $323,318
125,805 Added 399.06%
157,330 $363,000
Q3 2023

Nov 14, 2023

SELL
$2.51 - $3.55 $70,468 - $99,666
-28,075 Reduced 47.11%
31,525 $82,000
Q2 2023

Aug 14, 2023

SELL
$2.12 - $4.47 $946,908 - $2 Million
-446,655 Reduced 88.23%
59,600 $213,000
Q1 2023

May 15, 2023

BUY
$1.93 - $13.1 $977,072 - $6.63 Million
506,255 New
506,255 $1.1 Million
Q3 2022

Nov 14, 2022

SELL
$4.6 - $9.91 $2.19 Million - $4.72 Million
-476,542 Reduced 74.51%
163,015 $1.06 Million
Q2 2022

Aug 15, 2022

BUY
$3.72 - $9.0 $329,595 - $797,409
88,601 Added 16.08%
639,557 $2.93 Million
Q1 2022

May 16, 2022

BUY
$8.19 - $13.89 $1.22 Million - $2.07 Million
148,859 Added 37.02%
550,956 $4.77 Million
Q4 2021

Feb 14, 2022

BUY
$12.98 - $29.75 $5.22 Million - $12 Million
402,097 New
402,097 $5.74 Million

Others Institutions Holding ORMP

About ORAMED PHARMACEUTICALS INC.


  • Ticker ORMP
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 38,827,100
  • Market Cap $92M
  • Description
  • Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules or pills for delivery of polypeptides. Its proprietary flagship product is the ORMD-0801, an orally ingestible insulin capsule, which completed phase II clinical trials for th...
More about ORMP
Track This Portfolio

Track Two Sigma Investments, LP Portfolio

Follow Two Sigma Investments, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Investments, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Investments, LP with notifications on news.